Antonio Omuro, MD
Professor AdjunctDownloadHi-Res Photo
Cards
Contact Info
About
Titles
Professor Adjunct
Biography
Dr. Omuro is a Professor Adjunct in the department of Neurology at the Yale School of Medicine.
He is the former chief of the Division of Neuro-Oncology and Director of the Yale Brain Tumor Center. He is a graduate and former faculty of the Neuro-Oncology program at Memorial Sloan Kettering Cancer Center in New York. Dr. Omuro is an internationally renowned leader in clinical care and research in the field of brain tumors, having led pivotal research projects and clinical trials to advance the treatment of these difficult cancers.
Dr. Omuro is currently the chair of the Department of Neurology and Neurological Sciences at Stanford University.
Departments & Organizations
Education & Training
- Fellow
- Memorial Sloan Kettering Cancer Center (2004)
- MD
- Sao Paulo School of Medicine (1995)
Research
Overview
Dr. Omuro is an international leader in the research of brain tumors, having led pivotal research programs and clinical trials to advance the treatment of these difficult cancers.
Medical Research Interests
Central Nervous System Neoplasms; Clinical Trial; Glioblastoma; Meningeal Neoplasms
ORCID
0000-0003-4299-3664
Research at a Glance
Yale Co-Authors
Frequent collaborators of Antonio Omuro's published research.
Publications Timeline
A big-picture view of Antonio Omuro's research output by year.
Research Interests
Research topics Antonio Omuro is interested in exploring.
Sanjay Aneja, MD
MingDe Lin, PhD
Veronica Chiang, MD, FAANS
Tal Zeevi, MSc
Alexandria Brackett, MLIS, AHIP, MA
David A. Hafler, MD, FANA
265Publications
21,755Citations
Central Nervous System Neoplasms
Glioblastoma
Meningeal Neoplasms
Publications
2024
NIMG-30. DEUTERIUM METABOLIC IMAGING (DMI) SHOWS A STRONG RELATION BETWEEN TUMOR GRADE AND GLUCOSE METABOLISM IN PRIMARY BRAIN TUMORS
Thaw-Poon S, Blondin N, Liu Y, Corbin Z, Baehring J, Omuro A, Moliterno J, Omay S, Fulbright R, de Graaf R, De Feyter H. NIMG-30. DEUTERIUM METABOLIC IMAGING (DMI) SHOWS A STRONG RELATION BETWEEN TUMOR GRADE AND GLUCOSE METABOLISM IN PRIMARY BRAIN TUMORS. Neuro-Oncology 2024, 26: viii201-viii201. PMCID: PMC11553074, DOI: 10.1093/neuonc/noae165.0795.Peer-Reviewed Original ResearchConceptsGrade 2 lesionsTumor gradeDeuterium metabolic imagingMetabolic imagingNon-enhancing tumor regionsBrain tumorsTumor-to-brain contrastTumour-specific valuesActive tumor tissueImage contrastVOI-based analysisGrade 4Evaluate disease progressionTesla MRI scannerFDG-PETGrade 3Lesion gradeTumor tissuesDisease progressionDisease stageOral administrationTumorObservational studyNormal brainContrast enhancementJS07.4.A A PHASE 0/IA STUDY OF BRIGIMADLIN CONCENTRATION IN BRAIN TISSUE AND A DOSE ESCALATION STUDY OF BRIGIMADLIN PLUS RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Sarkaria J, Mrugala M, Jaeckle K, Burns T, Vaubel R, Parney I, Chaichana K, Clement P, Martínez-García M, Sanchez J, Omuro A, Pronk L, Ross H, Teufel M, Hesse R, Grempler R, Galanis E. JS07.4.A A PHASE 0/IA STUDY OF BRIGIMADLIN CONCENTRATION IN BRAIN TISSUE AND A DOSE ESCALATION STUDY OF BRIGIMADLIN PLUS RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology 2024, 26: v13-v13. PMCID: PMC11485993, DOI: 10.1093/neuonc/noae144.036.Peer-Reviewed Original ResearchConceptsNon-contrast-enhancedMouse double minute 2Contrast enhancementMGMT promoter unmethylated glioblastomaPatient-derived xenograft modelsUnbound concentrationsCalculated unbound concentrationsNewly diagnosed GBMMaximum tolerated doseNewly diagnosed glioblastomaTumor cell apoptosisSingle-arm trialMDM2-p53 antagonistsDouble minute 2Restore wild-typeBrain tissueBrain tumor tissueTP53 WTUnmethylated glioblastomaPhase 0Diagnosed glioblastomaTolerated doseOpen-labelP53 target gene expressionIDH-wtEnhancing Clinical Decision-Making: An Externally Validated Machine Learning Model for Predicting IDH Mutation in Gliomas using Radiomics from Pre-Surgical MRI
Lost J, Ashraf N, Jekel L, von Reppert M, Tillmanns N, Willms K, Merkaj S, Petersen G, Avesta A, Ramakrishnan D, Omuro A, Nabavizadeh A, Bakas S, Bousabarah K, De Lin M, Aneja S, Sabel M, Aboian M. Enhancing Clinical Decision-Making: An Externally Validated Machine Learning Model for Predicting IDH Mutation in Gliomas using Radiomics from Pre-Surgical MRI. Neuro-Oncology Advances 2024, vdae157. DOI: 10.1093/noajnl/vdae157.Peer-Reviewed Original ResearchAltmetricConceptsIsocitrate dehydrogenase mutation statusArea under the curveMagnetic resonance imagingMutation statusML modelsMachine learningSemi-automated tumour segmentationsPre-surgical magnetic resonance imagingCare of glioma patientsMachine learning modelsClinical care of glioma patientsIsocitrate dehydrogenase statusAnnotated datasetsFeature extractionPrediction taskMulti-institutional dataModel trainingIDH mutationsPredicting IDH mutationLearning modelsRetrospective studyHeterogeneous datasetsTumor segmentationGlioma patientsBrain tumorsA phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).
Sarkaria J, Mrugala M, Jaeckle K, Burns T, Vaubel R, Parney I, Chaichana K, Clement P, Martinez-Garcia M, Sepulveda Sanchez J, Omuro A, Pronk L, Ross H, Teufel M, Hesse R, Grempler R, Galanis E. A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM). Journal Of Clinical Oncology 2024, 42: 2017-2017. DOI: 10.1200/jco.2024.42.16_suppl.2017.Peer-Reviewed Original ResearchConceptsNon-contrast-enhancedOpen-labelContrast enhancementMGMT promoter unmethylated glioblastomaUnbound concentrationsCalculated unbound concentrationsNewly diagnosed GBMDose-escalation studyMaximum tolerated doseTumor cell apoptosisSingle-arm trialMDM2-p53 antagonistsRestore wild-typeBrain tissueUnmethylated glioblastomaBrain tumor tissueEscalation studyDiagnosed glioblastomaTolerated doseP53 target gene expressionPrimary endpointIDH-wtSolid tumorsTumor tissuesXenograft modelRadiotherapy Plan Quality Assurance in NRG Oncology Trials for Brain and Head/Neck Cancers: An AI-Enhanced Knowledge-Based Approach
Wang D, Geng H, Gondi V, Lee N, Tsien C, Xia P, Chenevert T, Michalski J, Gilbert M, Le Q, Omuro A, Men K, Aldape K, Cao Y, Srinivasan A, Barani I, Sachdev S, Huang J, Choi S, Shi W, Battiste J, Wardak Z, Chan M, Mehta M, Xiao Y. Radiotherapy Plan Quality Assurance in NRG Oncology Trials for Brain and Head/Neck Cancers: An AI-Enhanced Knowledge-Based Approach. Cancers 2024, 16: 2007. PMID: 38893130, PMCID: PMC11171017, DOI: 10.3390/cancers16112007.Peer-Reviewed Original ResearchAltmetricConceptsIntensity-modulated proton therapyPlan quality assuranceOrgan-at-riskRT planningQuality of radiation therapyClinical trialsIMPT plansKBP modelPlan QAPhoton plansRadiation therapyPhoton modelKBP plansTarget coveragePlan qualityProton therapyNasopharyngeal carcinomaMulti-institutional clinical trialsNRG Oncology trialsProton modelOutcomes of clinical trialsMulti-center clinical trialPhoton RTQuality assuranceHead/neck cancer
2023
CTNI-41. PHASE II AND PHASE 0 RESULTS OF ABTC 1801: A MULTI-ARM CLINICAL TRIAL OF THE PARP INHIBITOR PAMIPARIB WITH VERY LOW DOSE METRONOMIC TEMOZOLOMIDE IN RECURRENT IDH MUTANT GLIOMAS
Schiff D, Bindra R, Li J, Ye X, Ellingson B, Walbert T, Campian J, Nabors B, Lieberman F, Ozer B, Desai A, Omuro A, Wen P, Desideri S, Danda N, Grossman S. CTNI-41. PHASE II AND PHASE 0 RESULTS OF ABTC 1801: A MULTI-ARM CLINICAL TRIAL OF THE PARP INHIBITOR PAMIPARIB WITH VERY LOW DOSE METRONOMIC TEMOZOLOMIDE IN RECURRENT IDH MUTANT GLIOMAS. Neuro-Oncology 2023, 25: v84-v84. PMCID: PMC10639307, DOI: 10.1093/neuonc/noad179.0323.Peer-Reviewed Original ResearchCitationsConceptsObjective response rateArm AMetronomic temozolomideArm BGrade 3Non-enhancing tumorMeaningful objective response rateTumor/plasma ratioCumulative hematologic toxicityGrade 3 anemiaGrade 3 thrombocytopeniaGrade 4 neutropeniaPhase II componentArm clinical trialPhase IIKPS 90Median PFSHematologic toxicityPrimary endpointAlkylator therapyProgressive diseaseARM patientsMedian ageBRCAness phenotypeClinical trialsTrial in Progress: An Open-Label Expansion Trial Evaluating the Safety, PK/PD, and Clinical Activity of Emavusertib (CA-4948) + Ibrutinib in R/R Primary CNS Lymphoma
Grommes C, Nowakowski G, Rosenthal A, Lunning M, Ramchandren R, Regales L, Fowle M, Lane M, Wang C, Omuro A, Leslie L, Soussain C, Dabrowska-Iwanicka A, Ferreri A, Tun H. Trial in Progress: An Open-Label Expansion Trial Evaluating the Safety, PK/PD, and Clinical Activity of Emavusertib (CA-4948) + Ibrutinib in R/R Primary CNS Lymphoma. Blood 2023, 142: 3143. DOI: 10.1182/blood-2023-190391.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaInterleukin-1 receptor-associated kinase 4FMS-like tyrosine kinase 3Toll-like receptorsExpansion cohortPCNSL patientsDisease progressionRefractory primary central nervous system lymphomaDiagnosis of PCNSLCentral nervous system lymphomaPathogenesis of PCNSLSafety/tolerabilityOpen-label trialBlood-brain barrier penetrationPrimary CNS lymphomaSufficient blood-brain barrier penetrationNervous system lymphomaInitial clinical dataKey inclusion criteriaPotent oral inhibitorCentral nervous systemBrain barrier penetrationPK/PDTyrosine kinase 3Further preclinical studiesBSBM-18 SINGLE-CELL PROFILING TUMOR-INFILTRATING IMMUNE CELLS REVEALS CXCL13+ FOLLICULAR HELPER-LIKE CD4+ T CELLS IN HUMAN BRAIN TUMORS
Lu B, Lucca L, DiStasio M, Liu Y, Pham G, Buitrago-Pocasangre N, Arnal-Estape A, Moliterno J, Chiang V, Omuro A, Hafler D. BSBM-18 SINGLE-CELL PROFILING TUMOR-INFILTRATING IMMUNE CELLS REVEALS CXCL13+ FOLLICULAR HELPER-LIKE CD4+ T CELLS IN HUMAN BRAIN TUMORS. Neuro-Oncology Advances 2023, 5: iii4-iii4. PMCID: PMC10402449, DOI: 10.1093/noajnl/vdad070.014.Peer-Reviewed Original ResearchConceptsT cell populationsT cell functionT cellsHigh-grade gliomasBrain metastasesHuman brain tumorsImmune cellsBrain tumorsNon-small cell lung cancer brain metastasesB cellsAnti-PD-1 therapy responseCell lung cancer brain metastasesLung cancer brain metastasesProductive antitumor immune responsesFollicular helper T cellsT-cell receptor sequencingTumor-infiltrating T cellsAntitumor T-cell functionCancer brain metastasesCo-inhibitory receptorsAntitumor immune responseCell receptor sequencingLonger overall survivalCell functionTertiary lymphoid structuresImaging metabolism of deuterated glucose in patients with primary brain tumors
Corbin Z, Liu Y, Fulbright R, Thaw-Poon S, Baehring J, Blondin N, Kim P, Omuro A, Chiang V, Moliterno J, Omay S, Piepmeier J, Rothman D, de Graaf R, De Feyter H. Imaging metabolism of deuterated glucose in patients with primary brain tumors. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/0142.Peer-Reviewed Original ResearchThe Yale Glioma Dataset: Developing An Open Access, Annotated MRI Database
Sala M, Lost J, Tillmanns N, Merkaj S, von Reppert M, Ramakrishnan D, Bousabarah K, Huttner A, Aneja S, Avesta A, Omuro A, Aboian M. The Yale Glioma Dataset: Developing An Open Access, Annotated MRI Database. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/4511.Peer-Reviewed Original Research
News & Links
News
- October 12, 2022
Antonio Omuro, MD, elected a Fellow of the American Academy of Neurology
- March 24, 2021Source: Cancer Today
Immunotherapy Shows Promise for Treating Brain Metastases
- October 21, 2020
Susan Beris, MD, Brain Tumor CME Program
- May 29, 2020
Yale Cancer Center Investigator Shows Chemotherapy Combined with Low Doses of Radiotherapy Improves Survival for Patients with Rare Lymphoma
Related Links
Get In Touch
Contacts
Secondary Academic Office Number
Office Fax Number
Clinic Fax Number